Who are Finerenone (BAY 94-8862)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ACEI / ARB+finerenone, Finerenone (BAY94-8862).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/finerenone-bay-94-8862.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Finerenone (BAY 94-8862) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Finerenone (BAY 94-8862) (Finerenone (BAY 94-8862)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal mineralocorticoid receptor antagonist. Area: Cardiovascular, Nephrology.

marketed Non-steroidal mineralocorticoid receptor antagonist Mineralocorticoid receptor (MR) Cardiovascular, Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Finerenone (BAY 94-8862) (Finerenone (BAY 94-8862)) — University Medical Center Groningen. Finerenone is a non-steroidal mineralocorticoid receptor antagonist that blocks aldosterone signaling to reduce inflammation and fibrosis in the kidneys and cardiovascular system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Finerenone (BAY 94-8862) TARGET	Finerenone (BAY 94-8862)	University Medical Center Groningen	marketed	Non-steroidal mineralocorticoid receptor antagonist	Mineralocorticoid receptor (MR)
ACEI / ARB+finerenone	ACEI / ARB+finerenone	Capital Institute of Pediatrics, China	marketed	ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination	Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor
Finerenone (BAY94-8862)	Finerenone (BAY94-8862)	Bayer	phase 3	Non-steroidal mineralocorticoid receptor antagonist	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal mineralocorticoid receptor antagonist class)

Bayer · 1 drug in this class
University Medical Center Groningen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Finerenone (BAY 94-8862) — Competitive Intelligence Brief. https://druglandscape.com/ci/finerenone-bay-94-8862. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab